Background Pharmacotherapy provides an option for adults with overweight and obesity to
reduce their bodyweight if lifestyle modifications fail. We summarised the latest evidence for …

Background Pharmacotherapy provides an option for adults with overweight and obesity to
reduce their bodyweight if lifestyle modifications fail. We summarised the latest evidence for …

Aim To compare the benefits and harms of drugs approved for weight management in adults
with obesity or overweight. Materials and Methods We performed a systematic review of …

Long‐term pharmacotherapy for obesity and overweight - Padwal, RS - 2003 | Cochrane
Library Skip to Content Cookies Our site uses cookies to improve your experience. You can …

The OASIS 1 trial by Filip K Knop and colleagues1 demonstrates the greatest magnitude of
weight loss to date among oral anti-obesity medications. 2− 4 In this randomised, double …

Background We assessed the efficacy and safety of the oral glucagon-like peptide-1
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …

Background Obesity is a major public health issue, and new pharmaceuticals for weight
management are needed. Therefore, we evaluated the efficacy and safety of the glucagon …

The landscape of pharmacological interventions in combating obesity has long struggled
with the formidable challenge of balancing efficacy and safety, with weightloss drugs often …

Summary Background The Food and Drug Administration has approved several
pharmacotherapies for the treatment of obesity. This study assesses the cost‐effectiveness …

Objective: To review and compare the phase 3 clinical trial evidence on the 4 new
pharmacological agents approved for the management of overweight and obesity. Data …